CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05

CERO THERAPEUTICS HOLDINGS, INC.

Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.
Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.
Maximum aggregate borrowing up to $1,000,000 under the note.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.